BAP1 and renal cell carcinoma: Taken together, S/R RCC tumors are highly responsive to ICI-based therapies and an immune-inflamed microenvironment in S/R RCC may be driving these responses in a manner that is not completely dependent on BAP1, leading to improved survival on ICI.